BACKGROUND AND PURPOSE: Low serum concentrations of the amino acid homoarginine have been associated with endothelial dysfunction and an increased risk of all-cause and cardiovascular mortality. We aimed to investigate whether homoarginine levels are also associated with fatal strokes and a history of nonfatal cerebrovascular disease. METHODS: Serum homoarginine was measured in 3305 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study who were referred to coronary angiography at baseline (1997 to 2000) and were followed up with respect to mortality. RESULTS: During a median follow-up time of 9.9 years, 991 patients died including 61 fatal (ischemic and hemorrhagic) strokes. In a binary logistic regression analysis, the odds ratio (with 95% CI) for fatal stroke per SD of homoarginine was 0.52 (0.37 to 0.73; P<0.001) and remained significant after multivariable adjustments (0.62 [0.42 to 0.91]; P=0.014). For previous cerebrovascular disease events, the multivariable adjusted OR per SD of homoarginine was 0.82 (0.70 to 0.96; P=0.014). CONCLUSIONS: Low homoarginine levels are a novel risk factor for fatal strokes and are reduced in patients with a history of cerebrovascular disease. Further studies are needed to explore the significance of homoarginine to risk stratification and therapeutic approaches in the prevention of strokes.
BACKGROUND AND PURPOSE: Low serum concentrations of the amino acid homoarginine have been associated with endothelial dysfunction and an increased risk of all-cause and cardiovascular mortality. We aimed to investigate whether homoarginine levels are also associated with fatal strokes and a history of nonfatal cerebrovascular disease. METHODS: Serum homoarginine was measured in 3305 participants of the Ludwigshafen Risk and Cardiovascular Health (LURIC) study who were referred to coronary angiography at baseline (1997 to 2000) and were followed up with respect to mortality. RESULTS: During a median follow-up time of 9.9 years, 991 patients died including 61 fatal (ischemic and hemorrhagic) strokes. In a binary logistic regression analysis, the odds ratio (with 95% CI) for fatal stroke per SD of homoarginine was 0.52 (0.37 to 0.73; P<0.001) and remained significant after multivariable adjustments (0.62 [0.42 to 0.91]; P=0.014). For previous cerebrovascular disease events, the multivariable adjusted OR per SD of homoarginine was 0.82 (0.70 to 0.96; P=0.014). CONCLUSIONS: Low homoarginine levels are a novel risk factor for fatal strokes and are reduced in patients with a history of cerebrovascular disease. Further studies are needed to explore the significance of homoarginine to risk stratification and therapeutic approaches in the prevention of strokes.
Authors: S Pilz; A Meinitzer; A Tomaschitz; K Kienreich; A Fahrleitner-Pammer; C Drechsler; B O Boehm; W März Journal: Osteoporos Int Date: 2012-04-14 Impact factor: 4.507
Authors: S Pilz; A Meinitzer; A Tomaschitz; K Kienreich; H Dobnig; M Schwarz; D Wagner; C Drechsler; C Piswanger-Sölkner; W März; A Fahrleitner-Pammer Journal: Osteoporos Int Date: 2012-03-17 Impact factor: 4.507
Authors: Ilkka Seppälä; Niku Oksala; Antti Jula; Antti J Kangas; Pasi Soininen; Nina Hutri-Kähönen; Winfried März; Andreas Meinitzer; Markus Juonala; Mika Kähönen; Olli T Raitakari; Terho Lehtimäki Journal: Sci Rep Date: 2017-04-25 Impact factor: 4.379
Authors: Roman N Rodionov; Hoshimjon Begmatov; Natalia Jarzebska; Ketul Patel; Matthew T Mills; Zulaikha Ghani; Doreen Khakshour; Pankti Tamboli; Mitul N Patel; Mirette Abdalla; Maryann Assaf; Stefan R Bornstein; Jose Luis Millan; Stefanie M Bode-Böger; Jens Martens-Lobenhoffer; Norbert Weiss; Olga V Savinova Journal: J Am Heart Assoc Date: 2019-07-15 Impact factor: 5.501
Authors: Philipp Jud; Franz Hafner; Nicolas Verheyen; Andreas Meinitzer; Thomas Gary; Marianne Brodmann; Gerald Seinost; Gerald Hackl Journal: Sci Rep Date: 2018-09-21 Impact factor: 4.379